Kyverna therapeutics receives u.s. fda rmat designation for kyv-101 in the treatment of patients with progressive myasthenia gravis

The application was evaluated based on the positive clinical outcomes in patients treated in germany under the named-patient program the regenerative medicine advanced therapies designation allows kyverna to leverage on more expedited meetings and more senior fda leadership involvement throughout the development cycle for kyv-101 emeryville, calif. , aug. 12, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the designation as regenerative medicine advanced therapy (rmat) by the u.s. food and drug administration (fda) for its autologous, fully human cd19 chimeric antigen receptor (car) t-cell product candidate, kyv-101, to be used for the treatment of patients suffering from progressive myasthenia gravis.
PGR Ratings Summary
PGR Quant Ranking